Parisa Momtaz, MD
Melanoma Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Medical Director, Strategic Partnerships
- Clinical Director, Melanoma Service
I am a board-certified medical oncologist and internist specializing in the treatment of melanoma.
I understand that receiving a cancer diagnosis is difficult not only for the patient, but also for their entire network of support, because my decision to become a medical oncologist was motivated by the loss of a family member to cancer. This perspective guides my approach to patient care. To each patient visit, I bring empathy and compassion for the emotional side of a cancer diagnosis.
Beyond support, another principle of my care philosophy is education. Over the years, I have drawn upon my interactions with patients to develop a fact sheet that breaks down the elements of the disease and its treatment options. We go over the sheet together, talking about aspects like staging and the different types of treatment modalities. I make a point of taking the time to thoroughly characterize the disease and the available treatment options to empower my patients with the information they need about their diagnosis.
Read more
My practice is located at MSK Westchester in West Harrison, New York. Here, I work closely with a multidisciplinary team of surgeons, radiation oncologists, pathologists, nurses, and other specialists to provide the best care for our patients and their families. When I am not seeing patients, I am working to expand our regional care network. As the Medical Director of Strategic Partnerships at Memorial Sloan Kettering Cancer Center (MSK), I build relationships with partner hospitals around our regional locations in Long Island, New Jersey, and Westchester to support our goal of extending care closer to home for our patients outside of Manhattan.
I am also actively conducting research into the development of blood biomarkers for patients with melanoma whose tumor carries a specific mutation that can serve as a measure of how much melanoma is in the body. In time, I plan to evaluate these biomarkers’ utility in colorectal cancers in a clinical trial at MSK. I am passionate about improving therapeutic strategies for the treatment of both melanoma and GI cancers and have been fortunate to have my research supported by the American Society of Clinical Oncology.
A melanoma oncologist is a cancer doctor with special training in melanoma. This includes superficial spreading, nodular, lentigo maligna, and acral lentiginous melanomas, as well as eye, mucosal, and rare skin melanomas.
My Specialties
- Melanoma
Education
- MD, McGill Faculty of Medicine
Residencies
- Dermatology - New York Presbyterian/Weill Cornell Medical College
- Internal Medicine - Harvard University/Brigham and Women's Hospital
Awards and Honors
- American Society of Clinical Oncology, European Organisation for Research and Treatment of Cancer, and National Cancer Institute Grant for Diagnostic Development Tutorial and Markers in Cancer Conference in Brussels, Belgium (awarded to five candidates from the US/Canada, 2013)
- Wood Gold Medal for Outstanding Clinical Performance, McGill Faculty of Medicine (2008)
- Brian Netwon Memorial Award, McGill Faculty of Medicine (2008)
- Department of Medical Oncology Award for Outstanding Service, Dana-Farber Cancer Institute (2004)
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Momtaz sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Momtaz P, O’Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O’Reilly EM. Pancreas Cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer. 2021 Dec 1;127(23):4393-4402. Epub 2021 Aug 5. PMID: 34351646
Momtaz P, Harding JJ, Ariyan C, Coit DG, Merghoub T, et al. Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAF V600E/K mutation. Oncotarget. Sept 2017. PMID: 29285228
Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Dec 20; 7(51): 85430-85436. PMID: 27863426.
Momtaz P, Park V, Kelly N, Panageas K, Postow MA, Callahan M, Carvajal R, Dickson MA, D’Angelo S, Guillen J, Wolchok JD, Chapman PB. Safety of infusing Ipilimumab over 30 minutes. J Clin Oncol. 2015. Oct 20:33(30):3454-8. PMID: 26124475
Selected Book Chapters
Momtaz P, Halpern A, Kaley T, Pfister D,Groeger J, Krug L, “Basal and Squamous Cell Carcinoma”, “Astrocytoma”, “Nasopharyngeal Carcinoma”, “Spinal Cord Compression”, “Mesothelioma”, in Drilon A, Krug L, and Postow MA, Eds. Pocket Oncology, Lippincott Williams and Wilkins, Philadelphia, PA, March 2014.
Visit PubMed for a full listing of Dr. Momtaz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Parisa Momtaz discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].